Introducing the Galleri multi-cancer early detection test

Galleri is a blood test that can detect 50+ cancer types and can be taken annually.1,2

Check Eligibility and request your Galleri test
Already have an account? Log in

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Roger testimonial

The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Who is eligible?

The Galleri test is available at no cost to eligible NVIDIA employees and spouses/dependents, enrolled in a Cigna health plan, that also meet the eligibility criteria.

Employees

  • 50 years or older
    OR
  • 40-49 years old with certain risk factors
  • Not currently undergoing cancer treatment 
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic hepatitis B or C infection
    • Infection with certain strains of HPV (e.g., HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First-degree relative with cancer†
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2

*Excludes basal or squamous cell carcinoma of the skin.

†Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

woman with brown hair wearing a tan sweater and gray pants smiling softly and sitting on a chair in her living room

Dependents / Spouses

  • 50 years or older
    OR
  • 40-49 years old with certain risk factors
  • Not currently undergoing cancer treatment 
  • 40-49 years old AND at least one of the following risk factors:
    • Cancer survivor who has completed treatment at least 3 years ago*
    • Currently smokes or quit smoking less than 10 years ago
    • Diagnosis of cirrhosis or chronic hepatitis B or C infection
    • Infection with certain strains of HPV (e.g., HPV 16 or 18)
    • Known hereditary cancer syndrome
      • Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
  • 40-49 years old AND at least two of the following risk factors:
    • Documented genetic predisposition (germline variant)
    • First-degree relative with cancer†
    • History of HIV infection
    • Current use of immunosuppressive therapies after solid organ transplant
    • Diabetes
    • BMI:
      • Female ≥ 30 kg/m2
      • Male ≥ 35 kg/m2 

*Excludes basal or squamous cell carcinoma of the skin.

†Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.

Black couple sitting at their kitchen table writing on a notepad with a cup of coffee and a tablet on the table in front of them

Note to dependents: Use the employee’s [Access ID] [Galleri key] [Insurance information] when requesting the test. Use your personal information to request the test.

Already have an account? Log in

Limited data exists regarding the performance of the Galleri test in individuals <50 years of age.2,4,5

Galleri for NVIDIA

For Access ID, please use your Cigna member ID number, which can be found on the front of your Cigna ID card. If you don’t have an ID card, log into your myCigna app to view your digital Cigna card. 

  • Enter your name exactly as it appears on your Cigna ID card
  • Include the suffix ‘01’, ‘02’ of your Cigna ID for the Access ID

Eligible spouses or dependents need to create their own account when requesting their Galleri test

Eligible individuals can request the test once every 12 months from the time of the blood draw.

To create an account, use your personal email address. 

Screen for more in 4 simple steps

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Request the test

It will take about 10 minutes to complete an online health questionnaire about your medical history. The Galleri test, by GRAIL, is available by prescription only. By requesting the test and completing the questionnaire, you’re requesting a prescription from Recuro Health, an independent telemedicine provider.

illustrated graphic of the Galleri test box sitting on a table in front of a window

Receive a collection kit

If the Recuro Health telemedicine provider confirms your eligibility and prescribes the Galleri test, you will receive a notification via email and a collection kit in the mail. Visit Galleri.com/schedule to book your blood draw appointment at a GRAIL blood draw partner.

illustrated graphic of a white, gray haired female patient having her blood drawn

Provide your sample

Bring your test kit and Test Requisition Form (TRF) with you to the appointment. A trained technician will draw your blood sample and ship the kit to the GRAIL lab.

Illustrated graphic of a black man sitting in a blue armchair and reviewing test results on a tablet

Receive your results

Recuro Health will contact you when your result is ready — about 2-3 weeks after your blood is received at the GRAIL lab.

Already have an account? Log in

What does the Galleri test result mean?


The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 test has a Cancer Signal Detected result.4

This result will also include a prediction of the issue type or organ associated with the cancer signal, called a Cancer Signal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,5

In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.6*

*Based on the first ~25,000 participants with 1 year of follow-up. 

The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.

Cancer signal detected thumb
NEXT STEPS

A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imagining ordered by your healthcare provider to confirm cancer.

The Galleri test did not detect DNA fragments associated with cancer in your blood sample. 

Nearly 99% of people who use the Galleri test will screen negative.4

This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).7 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future. 

Cancer signal not detected thumb
NEXT STEPS

Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur, as this could lead to delayed diagnosis.

Cancer can be unpredictable. The Galleri test can be taken as a simple blood test. Adding the Galleri test to an annual routine can improve your chance of finding cancer early.8

Cancer screening with Galleri can make a difference

Galleri looks for many deadly cancers before symptoms appear from a single blood draw and identifies a unique “fingerprint” of 50+ cancers, including many without a recommended screening available today.
  • Jackiecompressed

    Patient testimonial: Jackie

    Cancer Signal Detected
    Read Jackie's full story

  • Cindy testimonial preview

    Patient testimonial: Cindy

    Cancer Signal Detected

  • Jonathan Testimonial Lyphoma

    Patient testimonial: Jonathan

    Cancer Signal Detected

  • Rich testimonials

    Patient testimonial: Rich

    Cancer Signal Detected

  • Mary patient vid

    Patient testimonial: Mary

    Cancer Signal Detected

  • Roger testimonial

    Patient testimonial: Roger

    Cancer Signal Detected

  • Valerie

    Patient testimonial: Valerie

    Cancer Signal Detected

  • Patient story video still closeup of Tami

    Patient testimonial: Tami

    No Cancer Signal Detected

  • patient story video still of Keith and his wife on a walk

    Patient testimonial: Keith

    No Cancer Signal Detected

  • Jennifer Testimonial poster

    Patient testimonial: Jennifer

    No Cancer Signal Detected
    Read Jennifer's full story

  • Rich S Taci

    Patient testimonial: Rich & Staci

    Cancer Signal Detected
    Read Rich & Staci's full story

  • Oncologist perspective

    Oncologist Perspectives

1 / 12

Frequently Asked Questions for NVIDIA 

Additional Frequently Asked Questions about the Galleri test

NVIDIA employees and spouses/dependents 50+ years of age, those 40-49 old with certain risk factors and enrolled in a NVIDIA Cigna health plan are eligible for the Galleri test.

Use of the Galleri test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

The Galleri test should be used in addition to healthcare provider recommended screening tests. Galleri is available by prescription only.

To access the Galleri test as a covered benefit, you must request the test through this web page. 

When you request the test, an independent telemedicine healthcare provider will review your request and order it if appropriate. The test is available by prescription only.

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit to eligible employees or spouses/dependents. 

An at-home or in-lab blood draw is included in the price of the test if scheduled with one of our partner labs. Find a time and location convenient for you.

When requesting the Galleri test you will need to provide an “Access ID” to confirm eligibility for the benefit. For NVIDIA the “Access ID” is your Cigna member ID, which can be found on the front of your Cigna card. If you don’t have a Cigna ID card, log into the myCigna app to access your digital ID card.

  • Enter your name exactly as it appears on your Cigna ID card
  • Include the suffix '01', '02' of your Cigna ID for the Access ID

If you are not eligible for the benefit under the NVIDIA program, you may be able to use pretax dollars in your flexible spending account (FSA) or health savings account (HSA) to pay for the Galleri test on Galleri.com. Check with your FSA or HSA administrator or insurance provider to determine eligibility.

Under the NVIDIA benefit program you will be able to complete the Galleri test every year.

To access the Galleri test as a covered benefit, you must request the test through this web page. An independent physician from Recuro Health will review your request and order the test, if appropriate.

The Galleri test is provided at no cost to eligible employees spouses/dependents only when obtained through this authorized site:  https://www.Galleri.com/NVIDIA

The blood draw associated with the Galleri test must occur on a date you are covered under this employee benefit.

Employees are responsible for the full cost of the test when obtained via any other means, such as a personal physician, or when the blood draw date of service occurs after the NVIDIA benefit coverage has ended.

Before proceeding to checkout, you should check the box to schedule a pretest consultation with an independent telemedicine provider. This step will allow you to ask any questions, such as about your risk and family history.

Under the NVIDIA benefit program you will be able to complete the Galleri test every year.

Get support

For questions about the Galleri test, please contact GRAIL Customer Service:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes

  1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
  3. American Cancer Society. Cancer facts & figures 2023. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html [GRAIL, Inc. Data on file: GA-2021-0065]
  4. Matrana M, Shukla V, Kingsbury D, et al. Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests [poster]. American Association for Cancer Research (AACR) Annual Meeting; 2025 Apr 25-30; Chicago. https://assets.grail.com/wp-content/uploads/2025/04/7202.Matrana.AACR-2025-RWE-100K_Poster_Final.pdf
  5. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
  6. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-59. doi: 10.1016/j.annonc.2020.02.011
  7. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347-76. doi: 10.1007/s10555-016-9629-x
  8. GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592] 
  9. American Cancer Society. Lifetime risk of developing or dying from cancer [cited 2025 Mar 11].  https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html
  10. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, Nov 2020 Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, Surveillance Research Program, released Apr 2021, based on the Nov 2020 submission. [Risk factor data on file: American Cancer Society Cancer Prevention Studies II/III]
  11. American Cancer Society. Understanding genetic testing for cancer risk [cited 2024 Mar 15]. https://www.cancer.org/cancer/risk-prevention/genetics/genetic-testing-for-cancer-risk/understanding-genetic-testing-for-cancer.html 
  12. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.
  13. Nabavizadeh N, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER2 study [proffered presentation]. European Society for Medical Oncology (ESMO) Annual meeting: 2025 Oct 17-21; Berlin.
  14. Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multi-cancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022; 192(10):1368-78. doi:10.1016/j.ajpath.2022.07.007